Trials / Active Not Recruiting
Active Not RecruitingNCT03844048
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
Conditions
- Chronic Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Acute Lymphoblastic Leukemia
- Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venetoclax | oral; film-coated tablets or tablets for oral suspension |
Timeline
- Start date
- 2019-09-06
- Primary completion
- 2027-08-01
- Completion
- 2027-08-01
- First posted
- 2019-02-18
- Last updated
- 2026-03-20
Locations
56 sites across 23 countries: United States, Australia, Austria, Belgium, Canada, Denmark, France, Greece, Hong Kong, Ireland, Japan, Mexico, New Zealand, Poland, Portugal, Russia, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03844048. Inclusion in this directory is not an endorsement.